EXOSOMES – A NEW FRONTIER IN CANCER THERAPY

Exosomes, also called exosome vesicles (EcVs), contain DNA, RNA (including mRNA, miRNA, and ncRNA), proteins, lipid layer molecules, metabolic enzymes, signal transduction molecules, and other components and are produced in the endosomes of almost all cells, tissues, and body fluids. As exosomal cargoes, they play key roles in signaling pathways, immune regulation, cellular development, carcinogenesis, and homeostasis, providing a potential portal for cell-free drug delivery systems. Exosomal components that vary from cell-to-cell and organ-to-organ, are used to evaluate a biological response. Thus, the variation in the exosomal components makes them promising candidates for biomarkers for cancer detection and diagnosis. Moreover, the recent advances in medicine have revealed that exosomes are capable of crossing the blood-brain barrier and transporting drugs. A growing number of studies have been conducted to understand the therapeutic potential of exosomes in cancer. Because exosomes alter the local and systemic environment for cancer cell development, inhibiting their release is an important treatment strategy. In addition to the targeted use of exosomes, there are also treatment approaches in cancer therapy in which exosomes are used directly for therapeutic purposes. However, previous studies show that exosomebased therapy is very promising. Nevertheless, further research is needed to determine unique biomarkers for clinical application. Therefore, the emerging therapeutic and regulatory potentials of exosomes in the field of cancer research are highlighted through a comprehensive literature review.

EXOSOMES – A NEW FRONTIER IN CANCER THERAPY

Exosomes, also called exosome vesicles (EcVs), contain DNA, RNA (including mRNA, miRNA, and ncRNA), proteins, lipid layer molecules, metabolic enzymes, signal transduction molecules, and other components and are produced in the endosomes of almost all cells, tissues, and body fluids. As exosomal cargoes, they play key roles in signaling pathways, immune regulation, cellular development, carcinogenesis, and homeostasis, providing a potential portal for cell-free drug delivery systems. Exosomal components that vary from cell-to-cell and organ-to-organ, are used to evaluate a biological response. Thus, the variation in the exosomal components makes them promising candidates for biomarkers for cancer detection and diagnosis. Moreover, the recent advances in medicine have revealed that exosomes are capable of crossing the blood-brain barrier and transporting drugs. A growing number of studies have been conducted to understand the therapeutic potential of exosomes in cancer. Because exosomes alter the local and systemic environment for cancer cell development, inhibiting their release is an important treatment strategy. In addition to the targeted use of exosomes, there are also treatment approaches in cancer therapy in which exosomes are used directly for therapeutic purposes. However, previous studies show that exosomebased therapy is very promising. Nevertheless, further research is needed to determine unique biomarkers for clinical application. Therefore, the emerging therapeutic and regulatory potentials of exosomes in the field of cancer research are highlighted through a comprehensive literature review.

___

  • Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2012;109(15):276-81.
Sağlık Bilimlerinde İleri Araştırmalar Dergisi-Cover
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2018
  • Yayıncı: İstanbul Üniversitesi
Sayıdaki Diğer Makaleler

IMPACT OF COMPREHENSIVE GENOMIC PROFILING NGS PANELS IN PRECISION ONCOLOGY: THE CITY OF HOPE CMDL EXPERIENCE

Milhan TELATAR

DISCOVERY OF NOVEL EPIGENETIC BIOMARKERS IN ORAL MALIGNANT LESIONS BY EPIGENOMICS AND TRANSCRIPTOMICS APPROACHES

Semra DEMOKAN, Sena SEN, Begum OZEMEK, Sevde COMERT, Onder ERYILMAZ, Murat ULUSAN, Necati ENVER, Uğur SEZERMAN, Gülsüm AK, Canan ALATLI, Mehmet Nejat DALAY

THERAPEUTIC IMPLICATIONS OF TARGETED SEQUENCING AND miRNA-SEQ OF B CELL LYMPHOMAS

Esra Esmeray SÖNMEZ, Tevfik HATİPOĞLU, Xiaozhou HU, Hongling YUAN, Ayça ERŞEN DANYELİ, Ayla ANAR ARICI, Ahmet ŞEYHANLI, Zühal ÖNDER SİVİŞ, Bengü DEMİRAĞ, Eda ATASEVEN, Dilek İNCE, Zekiye ALTUN, Safiye AKTAŞ, İnci ALACACIOĞLU, Tuğba SÜZEK, Nazan ÖZSAN, Taner Kemal ERDAĞ, Elvan Caglar CİTAK, Sermin ÖZ

NETWORK AND PATHWAY BASED ANALYSIS OF MULTI-OMIC DATA TO ENLIGHTEN MOLECULAR MECHANISMS OF COMPLEX DISEASES

Burcu GÜNGÖR

INVESTIGATION OF THE POTENTIAL EFFECTS OF YAP-1 AND NESTIN ON RISK CLASSES AND PROGNOSIS IN NEUROBLASTOMA

Selen KUM ÖZŞENGEZER, Burçin BARAN, Deniz KIZMAZOĞLU, Gamze SANLAV, Safiye AKTAŞ, Tekincan Çağrı AKTAŞ, Zekiye ALTUN, Nur OLGUN

APPLICATIONS OF TRANSCRIPTOMICS METHODS IN BREAST CANCER

Yesim GOKMEN-POLAR

POTENTIAL OF microRNAs AS A BIOMARKER FOR LARYNGEAL CANCER

Milad ASADİ, Ayse CANER, Venus ZAFARİ, Ahmad AL-OMAR, Can MUFTUOGLU, Shahram GHASEMBAGLOU

NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES

Semra DEMOKAN, Sena SEN, Onder ERYILMAZ, Sevde COMERT, Murat ULUSAN, Mehmet Nejat DALAY

miRNA-REGULATED PATHWAYS OF CD8+T CELLS IN TNBC MOUSE MODEL

Muge OCAL-DEMİRTAS, Doç. Dr. Bala GÜR DEDEOĞLU

DIETARY-BASED MOLECULAR TARGETS AND THERAPEUTIC OPPORTUNITIES IN CANCER

Gizem ÇALIBAŞI KOÇAL